retatrutide obesity triple hormone receptor agonist ⭐️topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating #retatrutide, an investigational GIP / GLP-1 / glucagon agonist, in adults with or “overweight” Lilly's triple agonist, retatrutide, delivered

Unlike the cardiac samples, we observed several HFpEF-specific clusters in our UMAP, including a cluster of periportal-like hepatocytes (highlighted in Figure S7A-B ) and the cluster of proliferating cells that was significantly enriched in HFpEF in our cell type composition analysis ( Figure S7A, B )

Opioids and anticholinergics can further slow GI motility, potentially leading to severe constipation or symptoms of gastroparesis

Phentermine for Weight Loss Warnings & Precautions Phentermine should be used with caution in some patient populations, especially those with preexisting cardiovascular conditions, like heart disease or uncontrolled hypertension

The GLP-1 journey: from discovery science to therapeutic impact